Lunsumio

Monotherapy for adult patients w/ relapsed or refractory follicular lymphoma who have received at least 2 prior systemic therapies.

IV 1 mg on cycle 1 day 1 as infusion over a min of 4 hr. 2 mg on cycle 1 day 8 as infusion over a min of 4 hr. 60 mg on cycle 1 day 15 as infusion over a min of 4 hr. 60 mg on cycle 2 day 1, may administer over 2 hr if infusions were well-tolerated in cycle 1. 30 mg on cycle 3+ day 1, may administer over 2 hr if infusions were well-tolerated in cycle 1. Duration of treatment: 8 cycles; additional 9 cycles should be administered if w/ partial response or have stable disease in response to treatment after 8 cycles unless unacceptable toxicity or disease progression occurs.

Hypersensitivity.

Cancer Immunotherapy

L01FX25 - mosunetuzumab ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.

POM